B6.129-Nrxn1^tm3Sud/J

Stock number: 021777
Research areas: Neurobiology Research, Research Tools

Description

The last coding exon (exon 24) of the Nrxn1 (neurexin 1) gene is flanked by loxP sites in this conditional mutant allele. Cre excision of the floxed segment enables the production of truncated protein. A 2xHA (hemagglutinin) tag outside of the floxed region provides a useful marker.

Detailed description

Neurexins act as cell adhesion molecules and receptors involved with synaptic function. In this conditional targeted mutation strain, the last coding exon (exon 24) of the Nrxn1 (neurexin 1) gene is flanked by loxP sites. Excision of the floxed segment through Cre recombinase expression effectively truncates the gene product. A 2xHA (hemagglutinin) tag outside of the floxed region provides a useful marker. Immunoblotting, immunohistochemistry, and immunocytochemistry confirm that the HA tag is functional.

Development

Exon 24, the last coding exon of the gene, encodes the transmembrane region of the protein as well as the cytoplasmic C-terminal. A 2xHA (hemagglutinin) tag followed by a loxP site was inserted in-frame into exon 24. A second loxP site was placed after the stop codon, immediately followed by an FRT-flanked PGK-neomycin resistance cassette. The mutation was created in (129X1/SvJ x 129S1/Sv)F1- Kitl⁺-derived R1 embryonic stem (ES) cells. This strain was backcrossed to C57BL/6 five times by the donating laboratory.

Allele

Symbol: Nrxn1^tm3Sud
Name: targeted mutation 3, Thomas C Sudhof
MGI accession ID: MGI:5468258
Generation method: Targeted
Attributes: Conditional ready (e.g. floxed); No functional change
Marker symbol: Nrxn1
Marker name: neurexin I
Chromosome: 17
Strain of origin: (129X1/SvJ x 129S1/Sv)F1-Kitl⁺
Molecular note: Exon 24, the last coding exon of the gene, encodes the transmembrane region of the protein as well as the cytoplasmic C-terminal. A 2xHA (hemagglutinin) tag followed by a loxP site was inserted in-frame into exon 24. A second loxP site was placed after the stop codon, immediately followed by an FRT-flanked PGK-neomycin resistance cassette.